**Supplemental table 1. Residual analysis for adverse event of chemoradiotherapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Adjusted standardized residual** | | | |
|  | **PEG tube use** | **NG tube** | **TPN** | **Oral intake alone** |
| **Fever** |  |  |  |  |
| **G0** | -2.921\* | -2.961\* | -3.400\* | 6.172\* |
| **G1** | 1.341 | 2.410\* | 0.179 | -2.599\* |
| **G2** | 1.953\* | 0.488 | 2.844\* | -3.702\* |
| **G3** | 0.816 | 1.222 | 2.908\* | -2.983\* |
| **Aspiration pneumonia** | |  |  |  |
| **–** | -0.995 | -4.809\* | -2.041\* | 4.455\* |
| **+** | 0.995 | 4.809\* | 2.041\* | -4.455\* |

PEG: percutaneous endoscopic gastrostomy, NG tube: nasogastric tube, TPN: total parenteral nutrition

\**p* < 0.05

**Supplemental table 2. Residual analysis for completion rate of chemoradiotherapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Adjusted standardized residual** | | | |
|  | **PEG tube use** | **NG tube** | **TPN** | **Oral intake alone** |
| **Completion** |  |  |  |  |
| **Yes** | 0.513 | -2.539\* | -1.785\* | 1.756\* |
| **No** | -0.513 | 2.539\* | 1.785\* | -1.756\* |

PEG: percutaneous endoscopic gastrostomy, NG tube: nasogastric tube, TPN: total parenteral nutrition

\**p* < 0.05